|
|
Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma
Paolo Antonio Ascierto
,
Michelle del Vecchio
,
Andrzej Mackiewicz
,
Caroline Robert
,
Vanna Chiarion-Sileni
,
et al.
Journal articles
inserm-03709901v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial
Paolo A Ascierto
,
Michele Del Vecchio
,
Caroline Robert
,
Andrzej Mackiewicz
,
Vanna Chiarion-Sileni
,
et al.
Journal articles
inserm-01807340v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Sonidegib improved quality of life in patients with advanced basal cell carcinoma: results from the phase 2 Basal Cell Carcinoma Outcomes with LDE225 Treatment trial through 73 weeks
Michael Migden
,
Carmen Loquai
,
Caroline Robert
,
Jean- François Baurain
,
Nicholas Squittieri
,
et al.
Journal articles
inserm-03818996v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|
|
|
Pimasertib Versus Dacarbazine in Patients With Unresectable NRAS-Mutated Cutaneous Melanoma: Phase II, Randomized, Controlled Trial with Crossover
Celeste Lebbé
,
Caroline Dutriaux
,
Thierry Lesimple
,
Willem Kruit
,
Joseph Kerger
,
et al.
Journal articles
hal-03256625v1
|
Share
Gmail
Facebook
Twitter
LinkedIn
More
|